John N Weinstein

Q: What Schools Are Affiliated With John N Weinstein

John N Weinstein is affiliated with the following schools: Harvard University, Iwate Medical University, MD Anderson Cancer Center, University of Minnesota, Massachusetts Institute of Technology, Stanford University, University of Virginia, University of Bern, University of California, San Francisco

John N Weinstein's AcademicInfluence.com Rankings

John N Weinstein

Chemistry

#2069

World Rank

#2920

Historical Rank

Organic Chemistry

#294

World Rank

#359

Historical Rank

chemistry Degrees

John N Weinstein

Engineering

#3101

World Rank

#4126

Historical Rank

Biomedical Engineering

#120

World Rank

#122

Historical Rank

Applied Physics

#505

World Rank

#523

Historical Rank

Electrical Engineering

#627

World Rank

#689

Historical Rank

engineering Degrees

Download Badge

Chemistry
Engineering

John N Weinstein's Degrees

Masters Computer Science Stanford University

Similar Degrees You Can Earn

Best Online Master's in Computer Science

Why Is John N Weinstein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John N Weinstein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comprehensive molecular portraits of human breast tumors (2012) (7791)
Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
Comprehensive molecular characterization of human colon and rectal cancer (2012) (6141)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008) (5775)
The Cancer Genome Atlas Pan-Cancer analysis project (2013) (5479)
Comprehensive molecular characterization of gastric adenocarcinoma (2014) (4496)
Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. (2013) (3821)
Integrated genomic characterization of endometrial carcinoma (2013) (3708)
The Somatic Genomic Landscape of Glioblastoma (2013) (3693)
Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) (2860)
The Immune Landscape of Cancer (2018) (2766)
Systematic variation in gene expression patterns in human cancer cell lines (2000) (2228)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015) (2211)
Genomic Classification of Cutaneous Melanoma (2015) (2143)
The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 (2011) (1652)
Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
Biomarkers in Cancer Staging, Prognosis and Treatment Selection (2005) (1587)
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017) (1514)
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma (2016) (1474)
A gene expression database for the molecular pharmacology of cancer (2000) (1461)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2017) (1446)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer (2015) (1332)
GoMiner: a resource for biological interpretation of genomic and proteomic data (2003) (1271)
Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin (2014) (1192)
An Information-Intensive Approach to the Molecular Pharmacology of Cancer (1997) (1134)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. (2017) (1092)
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation (2018) (984)
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. (1997) (944)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
Design of liposomes for enhanced local release of drugs by hyperthermia. (1978) (833)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas (2016) (826)
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance (2012) (799)
Integrated genomic and molecular characterization of cervical cancer (2017) (762)
Chemosensitivity prediction by transcriptional profiling (2001) (663)
Liposome-cell interaction: transfer and intracellular release of a trapped fluorescent marker. (1977) (644)
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. (2015) (601)
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas (2018) (600)
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
Nova regulates brain-specific splicing to shape the synapse (2005) (518)
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. (2004) (513)
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. (2012) (509)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
EDGAR: extraction of drugs, genes and relations from the biomedical literature. (1999) (495)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. (2013) (467)
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays (2003) (463)
A pan-cancer proteomic perspective on The Cancer Genome Atlas (2014) (437)
TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. (2015) (413)
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. (2012) (411)
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set (2006) (406)
Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. (1992) (386)
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. (2018) (381)
TCPA: a resource for cancer functional proteomics data (2013) (381)
Artificial neural networks improve the accuracy of cancer survival prediction (1997) (380)
Acetoacetylated Lipoproteins Used to Distinguish Fibroblasts from Macrophages In Vitro by Fluorescence Microscopy (1981) (377)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Interactions of liposomes with mammalian cells. (1978) (376)
The Pharmacology of Monoclonal Antibodies a (1987) (362)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. (2017) (361)
MicroRNAs modulate the chemosensitivity of tumor cells (2008) (360)
Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. (1979) (350)
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. (1990) (347)
Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A (1980) (345)
Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. (1986) (331)
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study (2007) (316)
Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. (1994) (314)
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition (2015) (307)
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution (2015) (307)
Neural computing in cancer drug development: predicting mechanism of action. (1992) (305)
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery (2007) (289)
Gadd45, a p53-Responsive Stress Protein, Modifies DNA Accessibility on Damaged Chromatin (1999) (285)
High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID) (2005) (281)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2018) (277)
Karyotypic complexity of the NCI-60 drug-screening panel. (2003) (277)
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. (1989) (276)
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. (2019) (273)
Small-sample precision of ROC-related estimates (2010) (273)
Integrated Molecular Characterization of Uterine Carcinosarcoma. (2017) (271)
Assessing the clinical utility of cancer genomic and proteomic data across tumor types (2014) (262)
MicroRNA expression profiles for the NCI-60 cancer cell panel (2007) (255)
MedMiner: an Internet text-mining tool for biomedical information, with application to gene expression profiling. (1999) (254)
Carboxyfluorescein as a probe for liposome-cell interactions effect of impurities, and purification of the dye (1981) (254)
TCGASpliceSeq a compendium of alternative mRNA splicing in cancer (2015) (250)
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use (2016) (241)
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines (2009) (240)
Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. (2008) (227)
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. (2018) (222)
Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. (1995) (218)
The Integrated Genomic Landscape of Thymic Epithelial Tumors. (2018) (210)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes (2014) (188)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts (2012) (185)
MatchMiner: a tool for batch navigation among gene and gene product identifiers (2003) (182)
Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq (2013) (180)
Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. (1995) (180)
An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". (1991) (175)
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples (2018) (173)
A stromal gene signature associated with inflammatory breast cancer (2008) (173)
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. (2003) (166)
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers (2018) (164)
Membrane Transporters and Channels (2004) (163)
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel (2006) (163)
Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. (1998) (162)
Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. (2001) (161)
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. (2006) (156)
Treatment of solid L1210 murine tumors with local hyperthermia and temperature-sensitive liposomes containing methotrexate. (1980) (155)
Liposomes as drug carriers in cancer chemotherapy. (1984) (153)
VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue (2013) (152)
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. (2005) (152)
DNA fingerprinting of the NCI-60 cell line panel (2009) (148)
mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities (2010) (146)
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters (2008) (146)
PRADA: pipeline for RNA sequencing data analysis (2014) (146)
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. (2008) (141)
The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. (2013) (138)
The Somatic Genomic Landscape of Glioblastoma (2014) (135)
Phase transition release, a new approach to the interaction of proteins with lipid vesicles. Application to lipoproteins. (1981) (132)
Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers (2013) (125)
Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. (1980) (125)
Selective delivery of liposome-associated cis-dichlorodiammineplatinum(II) by heat and its influence on tumor drug uptake and growth. (1981) (123)
Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers (2014) (123)
Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. (2006) (120)
Three microarray platforms: an analysis of their concordance in profiling gene expression (2005) (118)
Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. (2016) (117)
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells (2003) (115)
Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. (1997) (115)
Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. (2002) (114)
Voltage-dependent trans-bilayer orientation of melittin. (1982) (113)
VennMaster: Area-proportional Euler diagrams for functional GO analysis of microarrays (2008) (113)
Quantitative analysis of the formation and diffusion of A1-adenosine receptor-antagonist complexes in single living cells. (2004) (113)
Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". (1992) (112)
Mistaken Identifiers: Gene name errors can be introduced inadvertently when using Excel in bioinformatics (2004) (107)
Mining the NCI Anticancer Drug Discovery Databases: Genetic Function Approximation for the QSAR Study of Anticancer Ellipticine Analogues (1998) (107)
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise (2015) (106)
Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes (2014) (105)
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. (2005) (105)
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. (2018) (105)
Genetically encoding protein oxidative damage. (2008) (103)
ElemCor: accurate data analysis and enrichment calculation for high-resolution LC-MS stable isotope labeling experiments (2019) (102)
The Immune Landscape of Cancer. (2019) (99)
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. (2007) (96)
Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors (2006) (93)
Measurement of DNA concentration as a normalization strategy for metabolomic data from adherent cell lines. (2013) (93)
Monoclonal antibodies in the lymphatics: selective delivery to lymph node metastases of a solid tumor. (1983) (91)
Drug discovery: Cell lines battle cancer (2012) (91)
Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set (2010) (90)
Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers (2013) (90)
Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. (2003) (90)
Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines (2006) (90)
Antibody-mediated targeting of liposomes. Binding to lymphocytes does not ensure incorporation of vesicle contents into the cells. (1978) (89)
Analysis of ATP-Binding Cassette Transporter Expression in Drug-Selected Cell Lines by a Microarray Dedicated to Multidrug Resistances⃞ (2004) (89)
A protein expression database for the molecular pharmacology of cancer (1997) (89)
Mining and Visualizing Large Anticancer Drug Discovery Databases (2000) (88)
Erratum: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (Cell Reports (2017) 18(11) (2780–2794) (S2211124717302140) (10.1016/j.celrep.2017.02.033)) (2017) (88)
Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. (1994) (87)
Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells (2006) (87)
Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. (1987) (85)
Lateral diffusion of surface immunoglobulin, Thy-1 antigen, and a lipid probe in lymphocyte plasma membranes. (1979) (85)
AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. (2012) (83)
Sequencing and analysis of 10,967 full-length cDNA clones from Xenopus laevis and Xenopus tropicalis reveals post-tetraploidization transcriptome remodeling. (2006) (82)
Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. (1995) (82)
Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. (1998) (81)
Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. (1994) (81)
Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data (2002) (81)
Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines (2008) (80)
AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets (2007) (79)
Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer (2018) (79)
Liposome--lymphocyte interaction: saturable sites for transfer and intracellular release of liposome contents. (1977) (79)
Rapid mass spectrometric identification of proteins from two‐dimensional polyacrylamide gels after in gel proteolytic digestion (1997) (75)
Interaction of tubulin with phospholipid vesicles. I. Association with vesicles at the phase transition. (1981) (74)
Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. (2017) (73)
Pharmacogenomics--teaching old drugs new tricks. (2000) (73)
Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas (2013) (73)
Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. (1990) (72)
Characterization of long non‐coding RNA transcriptome in clear‐cell renal cell carcinoma by next‐generation deep sequencing (2015) (71)
Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. (1980) (71)
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. (2013) (70)
Metabolomics Reveals Attenuation of the SLC6A20 Kidney Transporter in Nonhuman Primate and Mouse Models of Type 2 Diabetes Mellitus* (2011) (69)
Assessment of Luminal and Basal Phenotypes in Bladder Cancer (2020) (68)
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers (2008) (68)
Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. (2004) (68)
BreakFusion: targeted assembly-based identification of gene fusions in whole transcriptome paired-end sequencing data (2012) (66)
Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS (1994) (66)
High‐density lipoprotein recombinants: evidence for a bicycle tire micelle structure obtained by neutron scattering and electron microscopy (1979) (65)
PurityEst: estimating purity of human tumor samples using next-generation sequencing data (2012) (64)
'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. (2002) (64)
An Artifact in LC-MS/MS Measurement of Glutamine and Glutamic Acid: In-Source Cyclization to Pyroglutamic Acid (2014) (64)
Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. (2010) (64)
Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. (1994) (64)
Biodistribution of monoclonal IgG1, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies. (1987) (63)
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. (2010) (63)
Monoclonal anitbodies in the lymphatics: toward the diagnosis and therapy of tumor metastases. (1982) (63)
Quality assessment of microarrays: Visualization of spatial artifacts and quantitation of regional biases (2005) (61)
Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. (2010) (61)
Integromic analysis of the NCI-60 cancer cell lines. (2004) (61)
Liposomes as drug carriers in cancer therapy. (1984) (60)
In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations (1992) (60)
Depicting combinatorial complexity with the molecular interaction map notation (2006) (59)
Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. (1989) (59)
TransVar: a multilevel variant annotator for precision genomics (2015) (59)
Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype (2017) (56)
Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition (2008) (56)
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. (2003) (55)
Transcriptomic analysis of the NCI-60 cancer cell lines. (2003) (53)
Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection. (1986) (52)
A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin. (1993) (52)
Human Apurinic/Apyrimidinic Endonuclease (Ape1) and Its N-terminal Truncated Form (AN34) Are Involved in DNA Fragmentation during Apoptosis* (2003) (52)
Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells (2007) (52)
Multifactorial Regulation of E-Cadherin Expression: An Integrative Study (2010) (52)
Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen (Cancer Research (January 15, 2008) 68 (415-424)) (2008) (51)
Molecular Interaction Maps--A Diagrammatic Graphical Language for Bioregulatory Networks (2004) (51)
Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution. (1991) (49)
Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477)) (2014) (49)
Inhibition of HIV-1 in monocyte/macrophage cultures by 2',3'-dideoxycytidine-5'-triphosphate, free and in liposomes. (1990) (48)
Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity (2016) (48)
Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. (2005) (48)
Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX. (2006) (45)
SpliceCenter: A suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies (2008) (45)
Report on EU–USA Workshop: How Systems Biology Can Advance Cancer Research (27 October 2008) (2009) (43)
Relative differences in the binding free energies of human immunodeficiency virus 1 protease inhibitors: a thermodynamic cycle-perturbation approach. (1991) (42)
Development of a robust classifier for quality control of reverse-phase protein arrays (2015) (42)
Voltage-dependent translocation of the asialoglycoprotein receptor across lipid membranes (1980) (42)
Sex differences in oncogenic mutational processes (2019) (41)
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database (2009) (41)
Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action. (1994) (41)
AbMiner: A bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies (2006) (39)
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial–mesenchymal transition (2014) (39)
Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance. (2008) (39)
Fc‐Receptor‐mediated Targeting of Antibody‐bearing Liposomes Containing Dideoxycytidine Triphosphate to Human Monocyte/Macrophages (1993) (39)
Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. (1994) (38)
Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody. (1987) (38)
NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas. (2017) (38)
Cancer: Discrepancies in drug sensitivity (2013) (37)
Monoclonal antitumor antibodies in the lymphatics. (1984) (36)
Binding of antigen-bearing fluorescent liposomes to the murine myeloma tumor MOPC 315. (1979) (36)
Optimization of monoclonal antibody delivery via the lymphatics: the dose dependence. (1986) (35)
High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner (2014) (35)
Comparison of a Neural Net-Based QSAR Algorithm (PCANN) with Hologram- and Multiple Linear Regression-Based QSAR Approaches: Application to 1, 4-Dihydropyridine-Based Calcium Channel Antagonists (2001) (34)
An approach to rapid estimation of relative binding affinities of enzyme inhibitors: application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease. (1996) (34)
Effect of liposome encapsulation of a fluorescent dye on its uptake by the lymphatics of the rat. (1981) (34)
The macroscopic and microscopic pharmacology of monoclonal antibodies. (1992) (33)
Aggregation and calcium-induced fusion of phosphatidylcholine vesicle-tubulin complexes. (1982) (33)
Erratum: Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas (Cell Reports (2019) 28(5) (1370–1384.e5), (S221112471930885X), (10.1016/j.celrep.2019.07.001)) (2019) (32)
The bioinformatics of microarray gene expression profiling. (2002) (32)
Targeted metabolomic analysis of amino acid response to L-asparaginase in adherent cells (2014) (32)
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. (2005) (32)
Exposing the cancer genome atlas as a SPARQL endpoint (2010) (30)
Interaction of tubulin with phospholipid vesicles. II. Physical changes of the protein. (1981) (30)
Chromatin challenges during DNA replication: a systems representation. (2008) (30)
Synergistic Drug Combinations in AIDS Therapy (1990) (30)
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia (2019) (30)
Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging. (1987) (29)
A curated census of autophagy-modulating proteins and small molecules (2014) (29)
Global analysis of tRNA and translation factor expression reveals a dynamic landscape of translational regulation in human cancers (2018) (28)
The mechanism of catalysis by L-asparaginase. (2020) (28)
[38] Carboxyfluorescein Leakage Assay for Lipoprotein-Liposome Interaction (1986) (28)
A Galaxy Implementation of Next-Generation Clustered Heatmaps for Interactive Exploration of Molecular Profiling Data. (2017) (28)
Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. (1987) (28)
Multiplexing siRNAs to compress RNAi-based screen size in human cells (2007) (27)
Searching for Pharmacogenomic Markers: The Synergy between Omic and Hypothesis-Driven Research (2002) (27)
Interactive Clustered Heat Map Builder: An easy web-based tool for creating sophisticated clustered heat maps. (2019) (26)
SpliceMiner: a high-throughput database implementation of the NCBI Evidence Viewer for microarray splice variant analysis (2007) (26)
Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. (2019) (26)
Framework for Identifying Common Aberrations in DNA Copy Number Data (2007) (26)
Lipid vesicle-cell interactions: analysis of a model for transfer of contents from adsorbed vesicles to cells. (1982) (26)
Karyotypic "state" as a potential determinant for anticancer drug discovery. (2005) (25)
Localized beta dosimetry of 131I-labeled antibodies in follicular lymphoma. (1992) (25)
Lymphatic delivery of monoclonal antibodies: potential for detection and treatment of lymph node metastases. (1985) (25)
Molecular targets in the National Cancer Institute drug screen (1995) (24)
RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis (2011) (24)
The EDGE hypothesis: Epigenetically directed genetic errors in repeat-containing proteins (RCPs) involved in evolution, neuroendocrine signaling, and cancer (2008) (23)
Catalytic Role of the Substrate Defines Specificity of Therapeutic l-Asparaginase. (2015) (23)
Antitumor activity of selective hyperthermia in tumor-bearing rats using thermosensitive magnetoliposomes as a new hyperthermic material (1997) (23)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Lysophosphatidylcholine in liposomal membranes: enhanced permeability but little effect on transfer of a water-soluble fluorescent marker into human lymphocytes. (1980) (22)
Induction of IL-2 receptor expression in vivo: response to concanavalin A. (1988) (22)
Specific interaction of myeloma tumor cells with hapten-bearing liposomes containing methotrexate and carboxyfluorescein. (1980) (22)
Development of Gene Ontology Tool for Biological Interpretation of Genomic and Proteomic Data (2003) (22)
COMBO: A New Approach to the Analysis of Drug Combinations in Vitro a (1990) (21)
New joint prediction algorithm (Q7-JASEP) improves the prediction of protein secondary structure. (1991) (21)
Global analysis of tRNA and translation factor expression reveals a dynamic landscape of translational regulation in human cancers (2018) (21)
Mapping the binding site of the nucleoside transporter protein: a 3D-OSAR study. (1990) (20)
The folding of ovalbumin. Renaturation in vitro versus biosynthesis in vitro. (1983) (20)
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. (2008) (20)
Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations (2015) (20)
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. (2019) (20)
Identification of Common Prognostic Gene Expression Signatures with Biological Meanings from Microarray Gene Expression Datasets (2012) (20)
Effect of dipyridamole on transport and phosphorylation of thymidine and 3'-azido-3'-deoxythymidine in human monocyte/macrophages. (1990) (19)
Asparagine synthetase: a new potential biomarker in ovarian cancer. (2009) (19)
Liposomes as "targeted" drug carriers: a physical chemical perspective (1981) (19)
Charge clusters and the orientation of membrane proteins (1982) (19)
Molecular targets in cancer drug discovery: cell-based profiling. (2000) (19)
The LeFE algorithm: embracing the complexity of gene expression in the interpretation of microarray data (2007) (18)
Application of the Electrotopological State Index to QSAR Analysis of Flavone Derivatives as HIV-1 Integrase Inhibitors (1996) (17)
Targeting of murine radiolabeled monoclonal antibodies in the lymphatics. (1987) (17)
Direct intralymphatic injection of radiolabeled 111In-T101 in patients with cutaneous T-cell lymphoma. (1991) (17)
Effects of thymidine and uridine on the phosphorylation of 3'-azido-3'-deoxythymidine (zidovudine) in human mononuclear cells (1991) (17)
Mutational Profiles Reveal an Aberrant TGF-β-CEA Regulated Pathway in Colon Adenomas (2016) (17)
Reconstitution of the hepatic asialoglycoprotein receptor with phospholipid vesicles. (1980) (16)
A user guide for the online exploration and visualization of PCAWG data (2020) (16)
Preliminary x-ray analysis of single crystals of ovalbumin and plakalbumin. (1983) (16)
In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation (2008) (15)
The interaction of apolipoprotein A-I with small unilamellar vesicles of L-alpha-dipalmitoylphosphatidylcholine. (1985) (15)
Carboxyfluorescein leakage assay for lipoprotein-liposome interaction. (1986) (15)
Concordance of Gene Expression and Functional Correlation Patterns across the NCI-60 Cell Lines and the Cancer Genome Atlas Glioblastoma Samples (2012) (15)
Antibody-Mediated Targeting of Liposomes (1982) (14)
Differential inhibition of 2'-deoxycytidine salvage as a possible mechanism for potentiation of the anti-human immunodeficiency virus activity of 2',3'-dideoxycytidine by dipyridamole (1991) (14)
Functional Categories Associated with Clusters of Genes That Are Co-Expressed across the NCI-60 Cancer Cell Lines (2012) (14)
Optimization of antigen presentation to T cell hybridomas by purified Ia molecules in planar membranes. Ia molecule polymorphism determines the antigenic fine specificity of the response to cytochrome c peptides. (1987) (14)
Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule. (2000) (13)
Interactive Clustered Heat Map Builder: An easy web-based tool for creating sophisticated clustered heat maps (2019) (13)
Connecting genes, drugs and diseases (2006) (13)
Dipyridamole binding to proteins in human plasma and tissue culture media. (1991) (12)
Clinical significance of FBXO17 gene expression in high-grade glioma (2018) (12)
Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer (2019) (12)
Thin-layer chromatography with agarose gels. A quick, simple method for evaluating liposome size. (1980) (12)
Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects (1994) (12)
Compartmental analysis of light-induced proton movement in reconstituted bacteriorhodopsin vesicles. (1982) (12)
In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI. (1995) (11)
Comparison of methods for sequential screening of large compound sets. (2006) (11)
Antibody-Mediated Drug Delivery (1990) (11)
Abstract 4262: A pan-cancer proteomic analysis of The Cancer Genome Atlas (TCGA) project (2014) (11)
SoS Notebook: an interactive multi-language data analysis environment (2018) (11)
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway (2021) (10)
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer (2020) (10)
Reference databases of cytokine structure and function. (1996) (10)
Is the Gene Expression Pattern of Lung Cancer Detected by Screening With Spiral Computed Tomography Different from That of Symptom-Detected Lung Cancer? (2004) (8)
Integrated transcriptomic–genomic tool Texomer profiles cancer tissues (2019) (8)
Site-directed mutagenesis of tryptophan residues to conserved hydrophobic residues inhibits the processing of human KB cell folate receptor. (1994) (8)
ZC3H12A Expression in Different Stages of Colorectal Cancer (2019) (8)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2020) (8)
Correction: Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas (2015) (8)
Chk 2 Molecular InteractionMap and Rationale for Chk 2 Inhibitors (2006) (8)
Network architecture of signaling from uncoupled helicase-polymerase to cell cycle checkpoints and trans-lesion DNA synthesis (2009) (7)
Neural network techniques for informatics of cancer drug discovery. (2000) (7)
Thread 4: Data discovery, transparency and visualization (2013) (6)
The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. (2015) (6)
Analysis of gene expression data of the NCl 60 cancer cell lines using Bayesian hierarchical effects model (2001) (5)
Cell line-based screening for new anticancer drugs (1994) (5)
Inference of large-scale topology of gene regulation networks by neural nets (2003) (5)
Integrated Systems and Technologies AMPK a Modulation in Cancer Progression : Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer (2012) (5)
Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) (2011) (5)
Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. (2017) (5)
Predicting high-risk endometrioid carcinomas using proteins (2018) (5)
A cDNA microarray gene expression database for cancer drug discovery (1999) (5)
Stress gene expression: analysis by informatics and functional genomics approaches (1999) (4)
The origin of bladder cancer from mucosal field effects (2021) (4)
Dipyridamole Potentiates the Activity of Zidovudine and Other Dideoxynucleosides against HIV‐1 in Cultured Cells a (1990) (4)
Genomic Assessment of Muscle-Invasive Bladder Cancer: Insights from the Cancer Genome Atlas (TCGA) Project (2018) (4)
Red Blood Cell-Encapsulation of L-Asparaginase Favorably Modulates Target Selectivity and Pharmacodynamics (2016) (4)
Pharmacokinetics and Organ Targeting of Monoclonal Antibodies (1989) (4)
Secondary structure of the human membrane-associated folate binding protein using a joint prediction approach. (1990) (4)
Online resources for PCAWG data exploration, visualization, and discovery (2017) (4)
Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway (2021) (3)
PathwaysWeb: a gene pathways API with directional interactions, expanded gene ontology, and versioning (2015) (3)
Abstract 3051: mRNA and microRNA expression profiles integrated with drug sensitivities of the NCI-60 human cancer cell lines (2010) (3)
for single-cell sequencing data (2020) (3)
Monoclonal Antibody Imaging of Human Melanoma (1986) (3)
Extracellular Domain Mutations in EGFR Occur Uniquely in Glioblastoma and Favor Ligand-independent Formation of the Active State (2012) (3)
Self-quenching of carboxyfluorescein fluorescence: Uses in studying liposome stability and liposome-cell interaction (2018) (3)
Genetic function approximation in the molecular pharmacology of cancer (1997) (3)
An epithelial-mesenchymal transition (EMT) gene signature to predict resistance to EGFR inhibition and AXL identification as a therapeutic target in head and neck squamous cell carcinoma. (2013) (3)
Investigation of PARP1 as a therapeutic target in small cell lung cancer. (2012) (3)
Therapeutic Target for Overcoming EGFR Inhibitor Resistance Resistance to EGFR and PI 3 K Inhibitors and Identifies Axl as a Mesenchymal Transition Gene Signature Predicts (2012) (2)
The Glutaminase Activity of L-Asparaginase Mediates Suppression of Asns Upregulation (2018) (2)
Linking Drugs and Genes: Pharmacogenomics, Pharmacoproteomics, Bioinformatics, and the NCI‐60 (2005) (2)
Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project (2015) (2)
Dipyridamole mediated enhanced antiproliferative activity of 10‐ethyl‐10‐deazaaminopterin (10‐EDAM) against human lung cancer cell lines (1996) (2)
A microarray analysis for differential gene expression using Bayesian clustering algorithm , ” support vector machines ( SVMs ) to investigate prostate cancer genes ” (2013) (2)
Use of Monoclonal Antibodies to Detect Metastases of Solid Tumors in Lymph Nodes (1985) (2)
Immunolymphoscintigraphy with Indium-111 labeled T101 monoclonal antibody (1985) (2)
MedMiner : An Internet Tool for Filtering and Organizing Biomedical Information (2007) (2)
USE OF MONOCLONAL ANTIBODIES FOR DIAGNOSIS AND THERAPY OF TUMOR METASTASES IN LYMPH NODES (1983) (2)
1 METABOLOMICS REVEALS ATTENUATION OF THE SLC 6 A 20 KIDNEY TRANSPORTER IN NONHUMAN PRIMATE AND MOUSE MODELS OF TYPE 2 DIABETES MELLITUS (2011) (2)
Thread 2: Network models (2013) (2)
Selective localization of liposomal encapsulated methotrexate in locally heated murine tumors (1979) (2)
MODULATION OF AUTOPHAGY AND ITS POTENTIAL FOR CANCER THERAPY. (2011) (2)
MicroRNAs in Cancer Pharmacology and Therapeutics: Exploiting a Natural Synergy between ‘-omic’ and Hypothesis-Driven Research (2011) (2)
Response envelope analysis for quantitative evaluation of drug combinations (2019) (2)
Ethanol induces a1-protease inhibitor mRNA in Hep 3B cells. (1991) (2)
A user’s guide to the online resources for data exploration, visualization, and discovery for the Pan-Cancer Analysis of Whole Genomes project (PCAWG) (2019) (2)
Regional delivery of monoclonal antitumor antibodies: detection and possible treatment of lymph node metastases. (1986) (2)
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial–mesenchymal transition (2014) (1)
Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project. (2014) (1)
A simple method for affinity purification of radiolabeled monoclonal antibodies. (1993) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19 (2022) (1)
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway (2021) (1)
Comparison of a Neural Net‐Based QSAR Algorithm (PCANN) with Hologram‐ and Multiple Linear Regression‐Based QSAR Approaches: Application to 1,4‐Dihydropyridine‐Based Calcium Channel Antagonists. (2001) (1)
Lipid model membrane studies on immune cytotoxic mechanisms. (1977) (1)
The design and characterization of temperature-sensitive liposomes (2018) (1)
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press. (2020) (1)
Delivery of Monoclonal Antibodies Through the Lymphatics: Characterization by Compartmental Modeling (1985) (1)
ASNS (asparagine synthetase) (2011) (1)
Abstract 3413: A pan-cancer atlas of genomic, epigenomic and transcriptomic alterations in the TGF-β pathway (2018) (1)
SpliceSeq 2.0: a tool for analysis and visualization of splicing variation in RNASeq data (2014) (1)
787 The Cancer Genome Atlas (TCGA) project analysis of micro-RNA and gene expression subtypes of high-grade, muscle-invasive urothelial carcinoma (2016) (1)
Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors. (2013) (1)
Biotechnology products in cancer therapy: a colloquium. (1988) (1)
Abstract A1-68: The long noncoding RNA SNHG18 promotes PPARγ function and luminal gene expression in muscle-invasive bladder cancer (2015) (1)
Predictive Pharmacology of Monoclonal Antibodies (1989) (1)
Immunolymphoscintigraphyin Patients with Lymphoma After SubcutaneousInjection of Indium-111-LabeledT 101 Monoclonal Antibody (1987) (1)
Comprehensive analysis of cancer stemness (2018) (1)
Voltage-dependent Changes of a Membrane Protein in Lipid Model Membranes: Studies with the Hepatic Asialoglycoprotein Receptor. (1982) (1)
Analysis by CGH of the tumor cell lines of the NCI anticancer drug discovery screen (1997) (1)
Integrative Analysis of NCI-60 Panel Reveals Candidate Key Genetic Regulators Affected by Genomic Alterations (2006) (1)
Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project. (2016) (1)
Information resources for liposome Research: The drug discovery program of the U.S. National cancer institute (1995) (1)
DNA sequence analysis of known cancer genes in the NCI-60 cell lines. (2006) (1)
Resource Reveals Molecular Classification Multiplatform Analysis of 12 Cancer Types within and across Tissues of Origin (0)
Ontogenomic study of the relationship between number of gene splice variants and GO categorization (2010) (0)
with Phosphoserine Escherichia coli Expanding the Genetic Code of (2011) (0)
Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer (BC) analysis. (2014) (0)
Asparagine synthetase is a biomarker of L-asparaginase activity in multiple cancer cell types (2008) (0)
Abstract 2979: A web portal of ‘next-generation’ clustered heat maps for user-friendly, interactive exploration of patterns in TCGA data (2015) (0)
MP72-06 THE LONG NON-CODING RNA SNHG18 PROMOTES PPARγ FUNCTION AND “LUMINAL” GENE EXPRESSION IN MUSCLE-INVASIVE BLADDER CANCER (2015) (0)
Abstract 5132: Interactively exploring patterns in TCGA data: a web-based compendium of ‘next-generation’ clustered heat maps. (2013) (0)
Abstract #1705: Transcript expression analysis of TOP1 at the exon level reveals potential intragenic regulation, association with DNA copy number, and is associated with genomic stability, and response to the indenoisoquinolines in the NCI-60 (2009) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
Abstract B156: An epithelial to mesenchymal transition (EMT) gene expression signature predicts resistance to PI3K/Akt pathway inhibitors in non-small cell lung cancer. (2011) (0)
Detection of tumor in lymph nodes by delivery of monoclonal antibodies via the lymphatics: An analysis of immunolymphoscintigraphy (1985) (0)
Abstract 5895: Whole-genome characterization of lung adenocarcinomas lacking alterations in RTK/RAS/RAF/MAPK pathway (2020) (0)
Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS (2011) (0)
ElemCor: accurate data analysis and enrichment calculation for high-resolution LC-MS stable isotope labeling experiments (2019) (0)
Abstract 1796: Analysis of TCGA RNASeq data using SpliceSeq provides a survey of alternative splicing in cancer. (2013) (0)
Abstract 4273: Integration with benchmark data of paired bulk and single-cell RNA sequencing data substantially improves the accuracy of bulk tissue deconvolution (2023) (0)
Abstract PD4-6: Combined analysis of gene expression, DNA copy number and mutation profiling data to display biological process anomalies in individual cancers (2013) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project (2016) (0)
Gene expression analysis of African-American and European-American breast tumors (2007) (0)
interaction: Saturable sites fortransfer and intracellular release ofliposome contents (1977) (0)
Abstract 968: Co-occurring genomic alterations define major subsets ofKRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities (2015) (0)
Use of a gene expression signature related to epithelial-to-mesenchymal transition (EMT) to predict for overall survival (OS) in cohorts of lung and head and neck cancer (HNSCC) patients. (2011) (0)
Publisher Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers (2020) (0)
CellMiner: A Database Tool for the NCI-60 Cancer Cell Lines (2008) (0)
Pharmacogenomic Study Expression Profiles in Human Colon Carcinoma Cells : A Impact of p 53 Knockout and Topotecan Treatment on Gene Updated (2003) (0)
Erratum: Sequencing and analysis of 10,967 full-length cDNA clones from Xenopus laevis and Xenopus tropicalis reveals post-tetraploidization transcriptome remodeling (Genome Research (2006) 16, (796-803)) (2006) (0)
Integrated transcriptomic–genomic tool Texomer profiles cancer tissues (2019) (0)
Trexate in locally heated murine tumors. Abstr. (1979) (0)
SCIMS: A new algorithm for associating anticancer drug mechanisms with gene ontology categories (2006) (0)
Abstract 970: Multi-layer and integrative analysis of the whole transcriptome in Asian gastric cancer: AMPKβ modulation in cancer progression (2012) (0)
Abstract A131: Identification of candidate therapeutic targets in mesenchymal head and neck squamous cell carcinoma. (2013) (0)
The distribution of neurofilament triplet proteins and protein gene product 9.5 in nerve fibres in the vertebral column of man and rat (1988) (0)
Comparison of mRNA and protein expression profiles in the NCI-60 cancer cell panel (2006) (0)
Abstract 887: Development of a robust nanoimmunoassay and immunohistochemical assay for asparagine synthetase (2012) (0)
Progression-specific markers in breast cancer obtained by microarray analysis are located to the malignant epithelial tumor cells (2006) (0)
Abstract LB-373: Comprehensive analysis of cancer stemness (2018) (0)
37 An epithelial to mesenchymal transition (EMT) gene expression signature identifies Axl as an EMT marker in non-small cell lung cancer (NSCLC) and head and neck cancer (HNC) lines and predicts response to erlotinib (2010) (0)
Abstract 1541: Co-mutations define major subsets of KRAS -driven lung adenocarcinoma with implications for targeted cancer therapy (2014) (0)
Abstract C149: Exon array analyses across the NCI‐60 reveals potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron (2009) (0)
Abstract 3788: Drug mechanisms of action: Triangulating with cultured cancer cells (2014) (0)
Liposome-mediated transfer of 6-carboxyfluorescein into lymphocytes: kinetics with and without metabolic inhibitors (1977) (0)
Abstract 161: Long noncoding RNA subtype classification of human prostate adenocarcinomas (2015) (0)
Clinical significance of FBXO17 gene expression in high-grade glioma (2018) (0)
Predicting High-Risk Endometrioid Endometrial Carcinomas Using Protein Biomarkers (2017) (0)
Abstract 5556: Identification of signaling pathways active in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC) by proteomic profiling (2010) (0)
Abstract 4837: Integrated genome sequence, epigenome, and transcriptome map of bladder cancer development (2011) (0)
Dose-and Time-dependent Effects Camptothecin-induced DNA Damage : Microarray Analysis of Transcriptional Regulation of Mitotic Genes by Updated (2002) (0)
GE-14TRANSCRIPTOMICPLASTICITYIS ASSOCIATED WITH THE TUMOR MICROENVIRONMENT IN GLIOBLASTOMA (2014) (0)
Substrate recognition by therapeutic L-Asparaginase: Asn vs Gln. (2015) (0)
Integrated genomic characterization of oesophageal carcinoma (2017) (0)
Genome-Wide Mapping and Subtype Classification of Long Non-Coding RNA in Acute Myeloid Leukemia (2014) (0)
COMBO: A new approach to the design and analysis of experiments on antiviral drug combinations (1991) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
THE P53 PATHWAY AND ANCESTRAL PROGENITORS ARE ASSOCIATED WITH TUMOR RECURRENCE IN GLIOBLASTOMA (2014) (0)
69: Patient Outcomes and Resource Utilization for Emergency Department Patients With Suspected Pulmonary Embolism and Initial Chest Computed Tomography Angiography Studies Deemed Suboptimal for Interpretation (2009) (0)
Non-Coding RNA modulate molecular subtype biology in muscle invasive bladder cancer (MIBC) and are independently associated with survival (2017) (0)
Enriched expression of PD-L1 and other immune targets after epithelial-mesenchymal transition (EMT) in squamous head and neck and lung cancers. (2015) (0)
Potentiation by dipyridamole of dideoxynucleoside activity against HIV-1: differential effects on salvage of deoxy- and dideoxy-nucleosides as a possible mechanism (1991) (0)
Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. (2023) (0)
COMBO: New Concepts and Methods for Designing and Analyzing Experiments on Combination Therapy (1992) (0)
Abstract B130: The intratumoral heterogeneity of glioblastoma suggests a pivotal role for clonal evolution. (2013) (0)
ZC 3 H 12 A Expression in Different Stages of Colorectal Cancer (2019) (0)
Targeted metabolomic analysis of amino acid response to L-asparaginase in adherent cells (2014) (0)
Abstract 291: Building a program in cancer bioinformatics and computational biology: A balancing act (2018) (0)
RPPA SPACE: an R package for normalization and quantitation of Reverse-Phase Protein Array data (2022) (0)
AbMiner: A relational database of validated antibodies and corresponding gene identifiers (2004) (0)
The Integrated Genomic L andscape of Thymic Epithelial Tumors Graphical (2018) (0)
Abstract 2991: Web-based access for whole genome analyses of gene expression, DNA copy number, microRNA transcript levels, drug activity, and their pattern comparisons for the NCI-60 (2012) (0)
Abstract 4137: Loss of LKB1 mediates an immune inert phenotype in human lung adenocarcinoma (2016) (0)
Abstract 5605:LKB1andKRASmutations predict resistance to PI3K/Akt inhibitors in non-small cell lung cancer (2012) (0)
Clinical Trial Update The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer (2015) (0)
Abstract 456: Defined co-mutation subgroups of KRAS-mutated NSCLC display distinct immune profiles (2015) (0)
Imaging , Diagnosis , Prognosis Tumor-Speci fi c Isoform Switch of the Fibroblast Growth FactorReceptor 2 Underlies theMesenchymal andMalignant Phenotypes of Clear Cell Renal Cell Carcinomas (2013) (0)
activity against ASNS-negative cells The glutaminase activity of l-asparaginase is not required for anticancer (2014) (0)
Probing Small-Molecule Degradation to Counter Enzyme Promiscuity. (2017) (0)
Abstract 984: Alteration of the p53 pathway is associated with subclonal tumor progression in glioblastoma (2014) (0)
Erratum: Monoclonal antibodies in the lymphatics: Selective delivery to lymph node metastases of a solid tumor (Science (423)) (1983) (0)
Abstract 5704: Pan-cancer genomic characterization of patient-matched primary, extracranial, and brain metastases (2020) (0)
AB007. OS02.01. The integrated genomic landscape of thymic epithelial tumors: a report by the TCGA research network (2017) (0)
OmicPioneer-sc: an integrated, interactive visualization environment for single-cell sequencing data (2020) (0)
Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers. (2023) (0)
Assessment of Luminal and Basal Phenotypes in Bladder Cancer (2020) (0)
E-cadherin promoter region methylation and its correlation with transcript level for the NCI-60 cancer cell lines (2004) (0)
The glutaminase activity of L-asparaginase determines its anticancer activity against ASNS-positive cancer cells. (2014) (0)
A user guide for the online exploration and visualization of PCAWG data (2020) (0)
the of cancer and proteomic data across tumor types. (2016) (0)
The Effects of the Organ Microenvironment on Metastatic Cell Gene Signatures (2017) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
Thread 5: Future directions (2013) (0)
609 Integrative analysis of DNA methylation and gene expression identifies a DNA methylation signature associated with erlotinib resistance in EGFR wild type non-small cell lung cancer cells (2010) (0)
Abstract 87: Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis (2021) (0)
Abstract 987: Comprehensive characterization of urothelial bladder cancer: a TCGA Project update (2014) (0)
Abstract 1982: Analyzing TCGA data: A novel, systems-oriented method for diagnosing batch effects and adjusting for them (2010) (0)
Comprehensivemolecularcharacterization of human colon and rectal cancer (2012) (0)
Lateral diffusion of surface immunoglobulin , Thy-I antigen , and a lipid probe in lymphocyte plasma membranes ( receptor mobility / fluorescence photobleaching / capping ) (0)
Abstract 1683: ATF4 down-regulation potentiates L-asparaginase activity in ovarian cancer cell lines (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John N Weinstein?

John N Weinstein is affiliated with the following schools:

John N Weinstein's Academic­Influence.com Rankings

John N Weinstein's Degrees

Similar Degrees You Can Earn

Why Is John N Weinstein Influential?

John N Weinstein's Published Works

Published Works

What Schools Are Affiliated With John N Weinstein?

John N Weinstein's AcademicInfluence.com Rankings